BR112015008279A2 - derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc) - Google Patents

derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc)

Info

Publication number
BR112015008279A2
BR112015008279A2 BR112015008279A BR112015008279A BR112015008279A2 BR 112015008279 A2 BR112015008279 A2 BR 112015008279A2 BR 112015008279 A BR112015008279 A BR 112015008279A BR 112015008279 A BR112015008279 A BR 112015008279A BR 112015008279 A2 BR112015008279 A2 BR 112015008279A2
Authority
BR
Brazil
Prior art keywords
hcc
oxo
treatment
hepatocellular carcinoma
derivative
Prior art date
Application number
BR112015008279A
Other languages
English (en)
Inventor
Bladt Friedheim
Friese-Hamim Manja
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112015008279A2 publication Critical patent/BR112015008279A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)

Abstract

resumo patente de invenção: "derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc)". a presente invenção refere-se a 3-(1-{3-[5-(1-metil-piperidin-4-ilmetóxi)-pirimidin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila ou um sal e/ou solvato farmaceuticamente aceitável da mesma para uso para o tratamento de carcinoma hepatocelular (hcc).
BR112015008279A 2012-11-02 2013-10-04 derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc) BR112015008279A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12007494 2012-11-02
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (1)

Publication Number Publication Date
BR112015008279A2 true BR112015008279A2 (pt) 2017-07-04

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008279A BR112015008279A2 (pt) 2012-11-02 2013-10-04 derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc)

Country Status (26)

Country Link
US (1) US20150283137A1 (pt)
EP (1) EP2914264B1 (pt)
JP (1) JP6255028B2 (pt)
KR (1) KR102131588B1 (pt)
CN (1) CN104768553A (pt)
AR (1) AR093318A1 (pt)
AU (1) AU2013339823B2 (pt)
BR (1) BR112015008279A2 (pt)
CA (1) CA2890273C (pt)
DK (1) DK2914264T3 (pt)
ES (1) ES2646913T3 (pt)
HK (1) HK1211869A1 (pt)
HR (1) HRP20171295T1 (pt)
HU (1) HUE035483T2 (pt)
IL (1) IL238536B (pt)
LT (1) LT2914264T (pt)
MX (1) MX354518B (pt)
NO (1) NO2914264T3 (pt)
PL (1) PL2914264T3 (pt)
PT (1) PT2914264T (pt)
RS (1) RS56485B1 (pt)
RU (1) RU2650679C2 (pt)
SG (1) SG11201503214YA (pt)
SI (1) SI2914264T1 (pt)
WO (1) WO2014067610A1 (pt)
ZA (1) ZA201503924B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015022782A1 (ja) 2013-08-14 2015-02-19 有限会社ジャパン通商 水耕栽培システム、および該水耕栽培システムと発泡スチロール製ハウスとを備えた植物工場
BR112022000266A2 (pt) * 2019-07-10 2022-05-17 Merck Patent Gmbh Preparação farmacêutica

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
EP2373640B1 (en) * 2009-01-08 2014-07-30 Merck Patent GmbH Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
JP2015536957A (ja) 2015-12-24
LT2914264T (lt) 2017-11-10
AR093318A1 (es) 2015-05-27
SG11201503214YA (en) 2015-05-28
KR102131588B1 (ko) 2020-07-08
PL2914264T3 (pl) 2017-12-29
SI2914264T1 (sl) 2017-12-29
AU2013339823A1 (en) 2015-06-18
MX354518B (es) 2018-03-08
CA2890273C (en) 2021-10-26
EP2914264B1 (en) 2017-08-09
CA2890273A1 (en) 2014-05-08
PT2914264T (pt) 2017-11-14
HK1211869A1 (en) 2016-06-03
EP2914264A1 (en) 2015-09-09
IL238536A0 (en) 2015-06-30
AU2013339823B2 (en) 2018-01-04
NO2914264T3 (pt) 2018-01-06
WO2014067610A1 (en) 2014-05-08
KR20150079942A (ko) 2015-07-08
RU2015120692A (ru) 2016-12-27
DK2914264T3 (en) 2017-09-11
US20150283137A1 (en) 2015-10-08
JP6255028B2 (ja) 2017-12-27
IL238536B (en) 2019-01-31
ZA201503924B (en) 2020-11-25
HRP20171295T1 (hr) 2017-10-20
RU2650679C2 (ru) 2018-04-17
ES2646913T3 (es) 2017-12-18
MX2015005265A (es) 2015-07-17
HUE035483T2 (hu) 2018-05-02
CN104768553A (zh) 2015-07-08
RS56485B1 (sr) 2018-01-31

Similar Documents

Publication Publication Date Title
HRP20182059T1 (hr) Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
DK3184523T3 (da) N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.
CL2013003306A1 (es) Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
BR112012030621A2 (pt) compostos para o tratamento de doenças associadas com clostridim difficile
BR112015021097A2 (pt) formulações de compostos orgânicos
AR093635A1 (es) Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion
BR112015008279A2 (pt) derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc)
BR112017012136A2 (pt) Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
MX2011007990A (es) Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma.
BR112017010232A2 (pt) Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um derivado de quinazolina
NZ708802A (en) Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound
BR112014011518A2 (pt) liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
MX359110B (es) Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek.
JP2015536957A5 (pt)
RU2016132401A (ru) Производное 6-оксо-1, 6-дигидро-пиридазина для применения для лечения почечно-клеточного рака (rcc)
PH12015500001A1 (en) Medicine against gastroesophageal reflux disease
Wei et al. Sorafenib combined with transarterial chemoembolization could improve the outcomes of patients with advanced hepatocellular carcinoma
TR200707406A2 (tr) Ş

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements